Verge

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, SAN, Tissue, News, Business development, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, CONVERGE, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Technology, Neurology, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Artificial Intelligence, Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, Tissue, News, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

FIFTH WALL CLOSES OUT STRONG 2023; PROMOTING 10 OF ITS TEAM MEMBERS AND ADDING 14 NEW COMPANIES TO ITS PORTFOLIO

Retrieved on: 
Tuesday, January 30, 2024
Hydrogen, SXSW, Hudson Pacific Properties, IMN, Climate Week NYC, Source, Carbon, MGM, CBRE, Property technology, EQR, Greenhouse, Invitation Homes, Blueprint, Like a Boss (film), Climate, BBVA, CO2, United Nations General Assembly, Verge, UN, ESG, Axios, Software, CNBC, Venetian, Investment, The Department, Public sector, Durst Organization, Host Hotels & Resorts, General Services Administration, COP28, VTS, American Homes 4 Rent, CIO, Kimco Realty, Human, Camden Property Trust, NMHC, Roadrunner, EV, MGM Resorts International

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Fifth Wall—the largest asset manager focused on improving, future-proofing, and decarbonizing the built world—announced that at the end of 2023, the Firm closed an additional $340M into its climate strategy on top of the $500M raised into its inaugural Climate Fund. Additionally, the Firm promoted 10 of its team members and added 14 new portfolio companies. Fifth Wall now has more than 110 strategic Limited Partners across 20 countries—approximately 300 investors worldwide—and in excess of 145 portfolio companies, maintaining its stance as the largest fund to invest globally in Built World Technology, including Property Technology (PropTech) and Climate Technology (Climate Tech).

Key Points: 
  • Additionally, the Firm promoted 10 of its team members and added 14 new portfolio companies.
  • "Fifth Wall helped define PropTech as an investment category and continues to meaningfully drive the sector's growth.
  • Fifth Wall now holds more than 110 PropTech portfolio companies, including Industrious , VERO , VTS , Neighbor , Bilt Rewards , Tailorbird , and WiredScore , amongst others.
  • Fifth Wall is proud to congratulate the following team member on their key 2024 promotions →

Lumin Fitness Finalizes First Franchise Agreement with Major 13-Unit Deal

Retrieved on: 
Tuesday, January 23, 2024
Environment, Partnership, Lumin, Verge, Automation, LED, Hilton Hotels & Resorts

DALLAS, Jan. 23, 2024 /PRNewswire/ -- Lumin Fitness, The World's Smartest Fitness Studio, announced today the signing of a 13-unit development deal with its first franchise partner, Verge Fit Holdings ("Verge"). This inaugural franchise agreement closely follows the brand's launch in late 2023 and outlines expansion plans for key Texas markets over the next three years including Austin, Houston and Dallas.

Key Points: 
  • DALLAS, Jan. 23, 2024 /PRNewswire/ -- Lumin Fitness , The World's Smartest Fitness Studio, announced today the signing of a 13-unit development deal with its first franchise partner, Verge Fit Holdings ("Verge").
  • When we were introduced to Lumin Fitness, it immediately resonated with us.
  • Lumin Fitness is revolutionizing the boutique fitness industry with an AI-infused fitness concept that utilizes the latest advances in technology to deliver a gamified and hyper-personalized workout experience in a group fitness setting.
  • Those interested in growth opportunities with Lumin Fitness can learn more during a live webinar scheduled for Tuesday, January 30, at 7 p.m. CT.

Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635

Retrieved on: 
Tuesday, January 9, 2024
Artificial intelligence, Patient, ALS, SAN, Verge, Tissue, FAAN, Drug discovery, Genomics, Disease, Safety, Therapy, Research, Health care

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform. VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform.

Key Points: 
  • The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform.
  • VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform.
  • In contrast, Verge's study harnesses the power of digital devices to collect thousands of objective, quantitative, relevant measurements directly from the patient, including mobility, breathing, and sleeping all from the comfort of their home.
  • “Incorporating cutting-edge technology into our ALS proof-of-concept study is a necessity born from the urgent unmet need to efficiently study promising therapeutics for people battling this devastating disease.

Flexjet Helps Naples Winter Wine Festival Bloom this year with Flight Hours and Helicopter Showcase

Retrieved on: 
Tuesday, December 19, 2023
Travel, NCEF, Sikorsky S-76, Verge, Sikorsky, Hope, Wine, Aircraft, Naples Winter Wine Festival, Safety, Fireworks

And in a first for the event, Flexjet will have its iconic Sikorsky S-76 helicopter on showcase during the festival.

Key Points: 
  • And in a first for the event, Flexjet will have its iconic Sikorsky S-76 helicopter on showcase during the festival.
  • Flexjet’s contributions for this year’s Naples Winter Wine Festival, scheduled for January 25-28, 2024, in Naples, Florida, include:
    Flexjet has expanded its commitment to the Naples Winter Wine Festival through the donation of helicopter flight hours, which this year makes its first appearance at the festival.
  • This luxury helicopter stands out for its safety redundancies including two pilots, two autopilots, two engines and a four-blade rotor system.
  • Since its first year of participation, donations by Flexjet are estimated to have generated more than $28 million for Naples-area charities.

Contemporary American Theater Festival announces new play commission

Retrieved on: 
Tuesday, December 5, 2023
Animal, Verge, McKowen, Fever Dream, Personality, Shepherd University, Thought, Firefly, CATF

Shepherdstown, WV, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shepherdstown, W.Va: The Contemporary American Theater Festival at Shepherd University, nationally known for developing and producing new plays, announces its twelfth play commission, Our Shepherdstown.

Key Points: 
  • Shepherdstown, WV, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shepherdstown, W.Va: The Contemporary American Theater Festival at Shepherd University, nationally known for developing and producing new plays, announces its twelfth play commission, Our Shepherdstown.
  • Based on the play Our Town by Thornton Wilder, Our Shepherdstown captures the unique and vibrant personality of historic Shepherdstown, West Virginia, and its people.
  • “New play commissions reflect contemporary society.
  • On Friday, December 8 at 6:30 p.m., CATF will celebrate the commission with a benefit that supports the Festival’s upcoming season.

BPM-PR Firm Wins Grand Prize for Strategy of the Year Award by PR Daily's Content Marketing Awards

Retrieved on: 
Thursday, December 14, 2023
Attention, Television, Woman, Verge, Organization, Life, Bellabeat, Beauty, Menopause, Roe v. Wade, Pregnancy, BPM, UVM, TIME, Meditation, Health, Strategy, Wellness, Prize, Jewellery, Content, PR, News, OBGYN, Endometriosis, Mashable

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- BPM-PR Firm, a leader in the PR and communications space, was awarded the Grand Prize for Strategy of the Year by PR Daily's Content Marketing Awards. PR Daily's Content Marketing Awards honor organizations and individuals who have demonstrated excellence in the field of content marketing and have made a significant impact on their industry. Winners represent an elite group of storytellers who know how to create content that stands out amongst the crowded media landscape. Their creative works have led to success for both their organizations and clients. The award spotlights BPM-PR Firm's work on the Bellabeat media campaign, which enacted a gracefully layered media approach for their Bellabeat Ivy, a wearable wellness tracker designed specially for women, and its corresponding mobile app. BPM-PR Firm's strategic vision resulted in a media campaign that generated over 195 media placements, not including television, with a total ad value estimate of over $34 million and a UVM (unique visitors per month) estimate of more than 3 million impressions. The 18-year-old boutique PR firm is known for crafting unique media messages that move the world by implementing innovative PR strategies and delivering unparalleled campaign results.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- BPM-PR Firm, a leader in the PR and communications space, was awarded the Grand Prize for Strategy of the Year by PR Daily's Content Marketing Awards .
  • PR Daily's Content Marketing Awards honor organizations and individuals who have demonstrated excellence in the field of content marketing and have made a significant impact on their industry.
  • "We are thrilled to be awarded the Grand Prize for Strategy of the Year by PR Daily.
  • For more information about BPM-PR Firm, media requests, and their PR Daily Content Marketing Strategy of the Year Award, please call 1.877.841.7244 or email [email protected] .

Amplify Her® Foundation Announces Inaugural Grantee Partners

Retrieved on: 
Monday, December 4, 2023
Verge, Organization, STEAM, AAPI, Entrepreneurship, New York Women's Foundation, Business incubator, Seed, European Leadership Network, Partnership, Growth, South Asian Youth Action, Amplify (company), Face, Education, Research report, Nursing, Management, Toy, Drug, Woman

NEW YORK, Dec. 4, 2023 /PRNewswire/ -- Amplify Her® Foundation today announced that it will grant a combined total of $1 million to New York City nonprofits working to advance the leadership of women and girls across the boroughs. Amplify Her® Foundation is a new private grantmaking foundation with the mission of supporting women and girls from underserved communities to become transformative changemakers.

Key Points: 
  • Amplify Her® Foundation is a new private grantmaking foundation with the mission of supporting women and girls from underserved communities to become transformative changemakers.
  • The grantee partners were chosen out of a pool of almost 150 requests for support.
  • "Our inaugural grantees are doing powerful and courageous work to advance women's leadership in New York City," said Marti Speranza Wong, Amplify Her® Foundation founder, executive director and board chair.
  • "We are extremely grateful to the Amplify Her Foundation for recognizing the untapped potential of girls of color and supporting our work.

Graphene Market: IDTechEx Provides An Outlook for the Coming Decade

Retrieved on: 
Monday, November 6, 2023
LG Chem, Research, Cabot, MWCNT, Textile, 2D, AGM, Players, Consultant, Verge, Benchmarking, Subscription business model, XG, Safety, Graphene, Carbon fibers, Birla

This is now changing, and over the next decade, IDTechEx forecast the graphene market to expand in a number of key application areas, reaching a market value of US$1.6 billion by 2034.

Key Points: 
  • This is now changing, and over the next decade, IDTechEx forecast the graphene market to expand in a number of key application areas, reaching a market value of US$1.6 billion by 2034.
  • IDTechEx has covered the graphene market comprehensively for over a decade, providing a detailed independent analysis of the technological and commercial progress of graphene and other 2D materials.
  • The commercialization has been making steady progress, and IDTechEx expects the graphene market to grow significantly over the next decade.
  • For more details on the graphene market, including segmentation by application area, see the IDTechEx market report " Graphene Market & 2D Materials Assessment 2024-2034: Technologies, Markets, Players ".